

Supplementary data

Table 2. Characteristics, etiology of infections and outcomes among 631 patients receiving carbapenem treatment according to hospital group.

		Group I	Group II	Group III
	Patients	174	249	208
	TYPE OF INFECTION			
	Community-acquired	64 (36.8)	110 (44.2)	119 (57.2)
	Nosocomial	78 (44.8)	78 (31.3)	54 (26.0)
	Healthcare associated	32 (18.4)	61 (24.5)	35 (16.8)
	FOCUS OF INFECTION			
	Urinary			78 (37.5)
	Intra-abdominal	44 (25.3)	89 (35.7)	55 (26.4)
	Respiratory	48 (27.6)	83 (33.3)	30 (14.4)
	Skin and soft tissue	41 (23.6)	44 (17.7)	32 (15.4)
	Unknown	22 (12.6)	22 (8.8)	3 (1.4)
	Febrile neutropenia	7 (4.0)	12 (4.8)	3 (1.4)
	Osteoarticular	7 (4.0)	4 (1.6)	3 (1.4)
	Others	4 (2.3)	0 (0.0)	3 (1.4)
		5 (2.9)	4 (1.6)	3 (1.4)
	Bacteremia			53 (25.5)
	Septic shock	27 (15.5)	56 (22.5)	30 (14.4)
		29 (16.7)	37 (14.9)	

		CULTURES		
Positive		115	156	120
Microorganisms isolated*	Escherichia coli	35 (30.4) 10 (8.7)	70 (44.9) 36 (23.1)	57 (47.5) 28 (23.3)
	• ESBL- producing E.coli	23 (20.0)	23 (14.7)	16 (13.3)
	Klebsiella pneumoniae	16 (13.9)	11 (7.1)	9 (7.5)
	• ESBL- producing K. pneumoniae	12 (10.4)	18 (11.5)	14 (11.7)
	Pseudomonas aeruginosa	1 (0.9)	1 (0.6)	0 (0.0)
	• P. aeruginosa MR	6 (5.2)	7 (4.5)	3 (2.5)
	Enterococcus spp.	5 (4.4)	4 (2.6)	3 (2.5)
	Staphylococcus aureus	1 (0.9)	2 (1.3)	3 (2.5)
	• MRSA	3 (2.6)	11 (7.1)	3 (2.5)
	Enterobacter spp.	3 (2.6)	3 (1.9)	5 (4.2)
	Proteus spp.	3 (2.6)	6 (3.9)	4 (3.3)
			1 (0.8)	
Mean treatment duration, days (± SD)		8.6 (±6.7)	8.2 (±5.3)	8.8 (±6.7)
REASONS FOR EMPIRICAL TREATMENT**				
TREATMENT	Severity	44 (25.3)	42 (16.9)	36 (17.3)
	Suspicion of ESBL-bacteria	31 (17.8)	46 (18.5)	20 (9.6)
	Suspicion of polymicrobial mixed infection	30 (17.2)	49 (19.7)	53 (25.5)
	Rescue	21 (12.1)	32 (12.9)	41 (19.7)
	Suspicion of Pseudomonas aeruginosa	17 (9.8)	23 (9.2)	8 (3.9)
	Adherence to local protocols	5 (2.9)	10 (4.0)	3 (1.4)
REASONS FOR DISCONTINUATION				

	De-escalation	72 (41.4)	87 (34.9)	71 (34.1)
	Completion of treatment	65 (37.4)	126 (50.6)	106 (51.0)
	Death	16 (9.2)	17 (6.8)	17 (8.2)
	Failure	13 (7.5)	13 (5.2)	6 (2.9)
	Adverse reactions	1 (0.6)	1 (0.4)	2 (1.0)

Data are given in n (%); *Percentages are referred to positive cultures; ** Multiple answers were allowed.

Group I, large university hospitals; Group II, medium-sized teaching hospitals; Group III, small hospitals.